Skip to content

Opus Genetics IRD Proceeds From Issuance In Connection With Registered Direct Offering

Proceeds From Issuance In Connection With Registered Direct Offering at other companies

American Battery Technology Company logo
American Battery Technology CompanyABAT
$3.75M
TMC the metals company Inc. logo
TMC the metals company Inc.TMC
$0-100%
TMC the metals company Inc. logo
TMC the metals company Inc.TMC
$0-100%
Assembly Biosciences logo
Assembly BiosciencesASMB
$0-100%
Phathom Pharmaceuticals, Inc. logo
Phathom Pharmaceuticals, Inc.PHAT
$121.97M
CBAK Energy Technology, Inc. logo
CBAK Energy Technology, Inc.CBAT
$70M+300%

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$339.35M+474%
Enterprise value$280.58M+887%
P/S28.3×+24.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept ird:ProceedsFromIssuanceInConnectionWithRegisteredDirectOffering.

The official record: Opus Genetics’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's proceeds from issuance in connection with registered direct offering.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's proceeds from issuance in connection with registered direct offering?
Opus Genetics (IRD) reported proceeds from issuance in connection with registered direct offering of $5.75M in Q4 2025.
What does proceeds from issuance in connection with registered direct offering mean?
Represents the gross cash proceeds received from the sale of equity securities through a registered direct offering. This is a vital metric for assessing the company's ability to access public capital markets to fund ongoing clinical trials. It highlights the company's success in securing external financing to extend its cash runway.